TABLE II.
Base-case analysis over 10-year time horizon
| Omalizumab + ICS | |
|---|---|
| Asthma-related events (per person-year) | |
| Hospitalizations | 0.31 |
| ED visits | 0.46 |
| Urgent care visits | 2.17 |
| Discounted QAM | 80.01 |
| Costs, discounted | |
| Chronic asthma cost without drug ($) | 7300 |
| Acute asthma cost ($) | 380 |
| Drug cost ($) | 123,000 |
| Total cost ($) | 131,000 |
| Cost-effectiveness ratios* | |
| Cost per QALY gained ($/QALY) | 821,000 |
| Cost per SFD gained ($/SFD) | 120 |
SFD, Symptom-free day.
*
All cost-effectiveness ratios are incremental compared with the nextleast-costly, undominated alternative. Reported ratios might not be precisely equal to the ratio of costs and effects because of rounding.